Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02190695 · ClinicalTrials.gov registry record · Phase 2
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT02190695: Completed Phase 2 study, sponsored by Fox Chase Cancer Center.
NCT02190695 is a Phase 2 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 92 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02190695, a Phase 2 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
The purpose of this study is to find a new way to treat Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). All the drugs are used to treat AML and MDS but are not usually combined together. The investigators are looking at both the safety and Efficacy of each combination.
Primary Outcome
evaluation of the complete and partial response rates (antileukemic effect) and the amount of time taken to achieve the response.
Interventions
- DRUG Carboplatin
- DRUG Decitabine
- DRUG Arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2013-04-01 |
| Est. Completion | 2020-04-16 |
| Phase | Phase 2 |
What the finished NCT02190695 record still lists
NCT02190695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02190695 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02190695 about?
NCT02190695 is a clinical study titled "Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS". The purpose of this study is to find a new way to treat Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). All the drugs are used to treat AML and MDS but are not usually combined together. The investigators are looking at both the safety and Eff...
What is the current status of trial NCT02190695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2013-04-01. Estimated completion is 2020-04-16.
What interventions are being tested in trial NCT02190695?
The interventions under investigation include: Carboplatin (DRUG), Decitabine (DRUG), Arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT02190695?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02190695's enrollment target sits among peer trials
92 767th of 2000 higher than 1,230 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI